Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT2 | P23786 | 1/20 | 0.50 |
| ▸ | CPT1A | P50416 | 1/20 | 0.50 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.50 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | PLA2G4B | P0C869 | 5/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.40 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3681659 | 0.93 | CPT2 (0.60) | CPT2CPT1ACPT1BACACBFFAR1 | |
| SCHEMBL3681655 | 0.93 | CPT2 (0.60) | CPT2CPT1ACPT1BACACBFFAR1 | |
| SCHEMBL14069946 | 0.83 | CPT2 (0.53) | CPT2CPT1ACPT1BSMPD1SUCNR1 | |
| SCHEMBL13409928 | 0.83 | ALDH1A1 (0.51) | ACACBFFAR1 | |
| SCHEMBL13410033 | 0.82 | S1PR1 (0.42) | ACACBFFAR1 | |
| SCHEMBL13410041 | 0.81 | CPT2 (0.51) | CPT2CPT1ACPT1BPLA2G4B | |
| SCHEMBL13409929 | 0.78 | POLB (0.53) | CPT2CPT1ACPT1BFFAR1SUCNR1 | |
| SCHEMBL4749052 | 0.77 | S1PR2 (0.36) | CPT2CPT1ACPT1BFFAR1 | |
| SCHEMBL4749043 | 0.77 | S1PR2 (0.36) | CPT2CPT1ACPT1BFFAR1 | |
| Trifluoroacetic Acid SCHEMBL3687516 | 0.77 | S1PR2 (0.37) | CPT2CPT1ACPT1BACACBFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410150-B2 | Inhibitors of carnitine palmitoyltransferase and treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2013-04-02 | — | — | US | disclosed |
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | CPT1A, CPT1B, CPT2 | CPT2 3/4885CPT1A 1/4885CPT1B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.